Literature DB >> 29029716

Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: New Horizons in the Interventional Management of Pulmonary Embolism.

Michael D Rivers-Bowerman1, Rebecca Zener1, Arash Jaberi1, Marc de Perrot2, John Granton3, John M Moriarty4, Kong T Tan5.   

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is an underdiagnosed potential complication of acute or recurrent pulmonary thromboembolic disease. Multiple studies suggest that up to 5% of patients with acute pulmonary thromboembolic disease go on to develop CTEPH. The prognosis of untreated CTEPH is poor, but advances in medical and surgical treatments over the past few decades have improved patient outcomes. The gold standard and curative treatment for CTEPH is pulmonary endarterectomy; however, some patients are inoperable and others who have undergone pulmonary endarterectomy experience persistent or recurrent pulmonary hypertension despite medical therapy. In recent years, balloon pulmonary angioplasty has emerged as a primary and adjunctive treatment for these CTEPH patients at expert or specialized centers. This review outlines an approach to balloon pulmonary angioplasty for CTEPH, including clinical presentation and evaluation; patient selection and indications; treatment planning; equipment and technique; overcoming technical challenges; recognition and management of complications; postprocedural care and clinical follow-up; and expected outcomes.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BPA; balloon pulmonary angioplasty; pulmonary hypertension

Mesh:

Year:  2017        PMID: 29029716     DOI: 10.1053/j.tvir.2017.07.011

Source DB:  PubMed          Journal:  Tech Vasc Interv Radiol        ISSN: 1557-9808


  1 in total

1.  Application of DynaCT angiographic reconstruction in balloon pulmonary angioplasty.

Authors:  Jie-Long Lin; Hai-Ming Chen; Feng-Cheng Lin; Jie-Ying Li; Cheng-Xin Xie; Wen-Liang Guo; Xiu-Fen Huang; Cheng Hong
Journal:  Eur Radiol       Date:  2020-07-03       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.